NCT07190430View on ClinicalTrials.gov

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 3, 2025

Primary Completion Date

February 16, 2026

Study Completion Date

February 16, 2026

Conditions
Atopic Dermatitis
Interventions
DRUG

PF-08049820

Administered orally

DRUG

Midazolam

Administered orally

DRUG

Dabigatran Etexilate

Administered orally

DRUG

Portia (EE and LN) or equivalent oral tablet

Administered orally

Trial Locations (1)

06511

RECRUITING

Pfizer Clinical Research Unit - New Haven, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT07190430 - A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants | Biotech Hunter | Biotech Hunter